Protein Partnership Specificity Explains Regional Brain Vulnerability in SCA1 and Beyond
Key Insights
Researchers at Baylor College of Medicine have uncovered why the cerebellum is selectively vulnerable in spinocerebellar ataxia type 1 (search) (SCA1) despite the disease-causing ATXN1 protein being expressed throughout the brain.
The study reveals that two forms of the partner protein Capicua (search) — CIC-Long and CIC-Short — have distinct binding preferences for ATXN1 and ATXN1L (search), respectively, driving tissue-specific toxicity.
Regional differences in the relative abundance of these protein forms dictate which brain areas are most affected, with the cerebellum showing the highest CIC levels.
Researchers at Baylor College of Medicine and the Duncan Neurological Research Institute (search) (Duncan NRI) at Texas Children's Hospital have provided a mechanistic explanation for one of the longstanding puzzles in neurodegenerative disease: why certain brain regions succumb to damage while others remain largely spared, even when the toxic protein driving the disease is present throughout the brain. Their findings, published in Genes & Development, focus on spinocerebellar ataxia type 1 (search) (SCA1) but carry implications that could extend to other neurological conditions.
"SCA1 is a rare neurodegenerative disorder characterized by progressive loss of coordination (ataxia), slurred speech and swallowing difficulties, which result from damage to the cerebellum, the brain region that controls coordination and balance," said corresponding author Dr. Huda Zoghbi, Distinguished Service Professor at Baylor, director of the Duncan NRI and a Howard Hughes Medical Institute investigator.
The Central Paradox of Selective Vulnerability
SCA1 is caused by a mutation in the ATAXIN-1 (search) (ATXN1) gene, which produces a faulty protein that is overly active and accumulates inside cells, ultimately damaging them. Although the human ATXN1 gene is expressed in many brain regions as well as other parts of the body — including the heart and liver — the cerebellum and brain stem bear the brunt of the pathology. This selective vulnerability has remained unexplained despite years of research into the disease.
Multiple prior studies from the Zoghbi lab had established that Capicua (search) (CIC) serves as an important partner protein for ATXN1. Yet CIC, like ATXN1, is expressed throughout the brain, raising the question of why it drives toxicity specifically in the cerebellum and not in other tissues affected in SCA1.
Two Forms of CIC, Two Distinct Biological Roles
The research team, led by first author Hamin Lee, a graduate student in the Zoghbi lab, approached the problem by examining the fundamental biology of these proteins. They knew that CIC exists in two forms: CIC-Long (CIC-L) and CIC-Short (CIC-S). Both ATXN1 and its related protein ataxin-1 (search)-like (ATXN1L (search)) bind to the same section on both CICs, but CIC-L and CIC-S differ at one end of the protein — a structural distinction that suggested distinct biological roles.
To test this, the researchers genetically engineered mice to lack only one CIC form at a time. The results were striking. Many mice without CIC-S died early in life and exhibited developmental problems, particularly in the lungs; some also developed hydrocephalus, an abnormal buildup of cerebrospinal fluid within the brain's cavities. In contrast, mice without CIC-L survived but developed behavioral problems, learning and memory difficulties, movement deficits, and hyperactivity.
"These findings showed that the two forms of CIC are not interchangeable, each has its own essential function," Lee said.
Specific Protein Partnerships Drive Tissue Vulnerability
The team then examined how the two CIC forms interact with ATXN1 and ATXN1L (search). They discovered that the pairings are specific: CIC-L preferentially binds ATXN1, while CIC-S preferentially binds ATXN1L. Loss of ATXN1 affects CIC-L protein stability more, which may underlie the similar disease characteristics observed between ATXN1 loss and CIC-L loss.
Critically, the levels of these proteins vary depending on the brain region and developmental stage. The cerebellum has the highest levels of CIC, which may render it especially vulnerable to overactive ATXN1. During lung development, ATXN1L (search) levels peak alongside high levels of CIC-S. "This means that certain areas are more vulnerable if a specific protein partnership is disrupted," Lee explained.
The study also highlighted that lacking ATXN1 does not cause ataxia but instead leads to learning and memory deficits, and Atxn1 knock-out in mice increases amyloid beta production — all characteristics associated with Alzheimer's disease and affecting the cortex and hippocampus, not the cerebellum. Meanwhile, eliminating ATXN1L (search) in animal models produced lung defects, perinatal mortality, and hydrocephalus.
Therapeutic Implications
"Our findings show that subtle differences in the relative abundance of CIC and ATXN1 forms at the protein level, together with the differential complexes they assemble, can result in highly specialized functions and dictate regional vulnerability," Zoghbi said. "Our study illuminates an improved understanding of neurological disease and offers new possibilities to comprehend and treat these conditions more effectively."
The research suggests that directing therapies to specific protein forms — rather than broadly targeting the entire ATXN1-CIC network — may yield more precise and effective treatments for SCA1. This principle of protein-form-specific targeting could also apply to other neurodegenerative conditions where similar mechanisms of selective vulnerability remain unexplained.
The study was supported by funding from the National Institute of Aging (F31 AG077918), the National Institute of Neurological Disorders and Stroke (R01 NS027699), the National Heart, Lung, and Blood Institute (R01 HL181470), the Howard Hughes Medical Institute, and several additional foundations and NIH centers.